As filed with the Securities and Exchange Commission on May 14, 2003
                                                    Registration No. 333________

================================================================================


                                  UNITED STATES
                       SECURITIES AND EXCHANGE COMMISSION
                             WASHINGTON, D.C. 20549
                                  -------------

                                    FORM S-8
                             REGISTRATION STATEMENT
                        UNDER THE SECURITIES ACT OF 1933
                                  -------------

                              HYCOR BIOMEDICAL INC.
             (Exact name of registrant as specified in its charter)

               Delaware                                58-1437178
     (State or other jurisdiction of        (I.R.S. Employer Identification No.)
     incorporation or organization)


    7272 Chapman Avenue                                             92841
  Garden Grove, California                                       (Zip Code)
   (Address of Principal
     Executive Offices)

                                 --------------


                              HYCOR BIOMEDICAL INC.
                             2001 STOCK OPTION PLAN
                            (Full title of the plan)

                                 --------------

                                Reginald P. Jones
                Senior Vice President and Chief Financial Officer
                              Hycor Biomedical Inc.
                               7272 Chapman Avenue
                         Garden Grove, California 92841
                     (Name and address of agent for service)

                                 (714) 933-3000
          (Telephone number, including area code, of agent for service)


                 Please address a copy of all communications to:
                             Stephen D. Cooke, Esq.
                      Paul, Hastings, Janofsky & Walker LLP
                              695 Town Center Drive
                                Seventeenth Floor
                        Costa Mesa, California 92626-1924
                                 (714) 668-6200
                                 --------------

<TABLE>
<CAPTION>

                         CALCULATION OF REGISTRATION FEE
====================================================================================================================================
                                                              Proposed maximum
  Title of each class of securities     Amount to be           offering price         Proposed maximum              Amount of
         to be registered                registered             per share(1)      aggregate offering price      registration fee
------------------------------------------------------------------------------------------------------------------------------------
<S>                                    <C>                          <C>                     <C>                          <C>
         Common Stock,
   par value $0.01 per share           1,000,000 shares             $2.95                   $2,948,320                   $238.52
====================================================================================================================================
</TABLE>

      (1)  361,000  shares were  calculated  pursuant  to Rule  457(h)(1)  at an
aggregate offering price of $724,600.  639,000 shares were calculated  pursuant
to Rules  457(c) and  457(h)(1),  based on the  average of the high and low sale
prices  ($3.48 per share) of the Common  Stock of the  Registrant  on the Nasdaq
Stock Market on May 13, 2003.
================================================================================


<PAGE>


                                     PART I

              INFORMATION REQUIRED IN THE SECTION 10(a) PROSPECTUS

ITEM 1.     Plan Information*

ITEM 2.     Registrant Information and Employee Plan Annual Information*

            *Information required by Part I to be contained in the Section 10(a)
            prospectus is omitted from the Registration  Statement in accordance
            with Rule 428(a)(1)  under the Securities Act and the Note to Part I
            of Form S-8.

                                     PART II

               INFORMATION REQUIRED IN THE REGISTRATION STATEMENT

ITEM 3.     INCORPORATION OF DOCUMENTS BY REFERENCE

            The   following   documents  are  hereby   incorporated   into  this
            Registration Statement and made a part hereof by this reference:

            (a)  The Annual  Report on Form 10-K of Hycor  Biomedical  Inc. (the
                 "Company") for the fiscal year ended  December 31, 2002,  filed
                 with the  Securities  and  Exchange  Commission  ("Commission")
                 pursuant to the  Securities  Exchange  Act of 1934,  as amended
                 (the "Exchange Act");

            (b)  All other reports  filed  pursuant to Section 13(a) or 15(d) of
                 the  Exchange  Act since the end of the fiscal year  covered by
                 the Registrant document referred to in (a) above; and

            (c)  The  description of the common stock contained in the Company's
                 registration  statement  filed under Section 12 of the Exchange
                 Act, including any amendment or report filed for the purpose of
                 updating such description.


           In addition,  all documents  filed by the Company with the Commission
pursuant to Sections  13(a),  13(c),  14 and 15(d) of the Exchange Act, prior to
the filing of a  post-effective  amendment  which  indicates that all securities
offered  have been  sold or which  deregisters  all  securities  then  remaining
unsold,  shall be deemed to be incorporated by reference into this  Registration
Statement and to be a part hereof from the date of filing of such documents with
the Commission.

ITEM 4.     DESCRIPTION OF SECURITIES

            Not applicable.

ITEM 5.     INTERESTS OF NAMED EXPERTS AND COUNSEL

            Not applicable.

ITEM 6.     INDEMNIFICATION OF DIRECTORS AND OFFICERS

           Section 145 of the  Delaware  General  Corporation  Law  authorizes a
court to award, or a corporation's  Board of Directors to grant  indemnification
to  directors  and  officers  in  terms   sufficiently   broad  to  permit  such
indemnification under certain circumstances against reasonable expenses incurred
in defending  against a claim.  Article Twelfth of the Company's  Certificate of
Incorporation,  as  amended,  provides  for  indemnification  of its  directors,
officers,  employees  and other  agents to the maximum  extent  permitted by the
Delaware  General   Corporation  law.  The  bylaws  of  the  Registrant  provide
indemnification of its officers and directors to the fullest extent authorized.

ITEM 7.     EXEMPTION FROM REGISTRATION CLAIMED

            Not applicable.


<PAGE>


ITEM 8.     EXHIBITS

            The exhibits  filed as part of this  Registration  Statement  are as
            follows:

     4      Hycor Biomedical Inc. 2001 Stock Option Plan  (incorporated by
            reference  as Exhibit A to the  Company's  Schedule  14A filed
            with the Commission on May 2, 2001).

     5      Opinion of Paul, Hastings, Janofsky & Walker LLP as to the
            legality of the securities being registered.

   23.1     Consent of Deloitte & Touche LLP.

   23.2     Consent of Paul, Hastings,  Janofsky & Walker LLP (included in
            the opinion filed as Exhibit 5).

    24      Power of Attorney  authorizing J. David Tholen and Reginald P.
            Jones to sign  amendments  to this  Registration  Statement on
            behalf of officers and directors of the Registrant  (contained
            on Signature Page of Registration Statement)

ITEM 9.     UNDERTAKINGS

(1)         The Company hereby undertakes:

            (a)   To file,  during any period in which offers or sales are being
                  made,  a   post-effective   amendment  to  this   Registration
                  Statement:

                  (i)    To include any prospectus  required by Section 10(a)(3)
                         of the Securities Act;

                  (ii)   To  reflect  in the  prospectus  any  facts  or  events
                         arising after the effective  date of this  Registration
                         Statement (or the most recent post-effective  amendment
                         thereof)  which,  individually  or  in  the  aggregate,
                         represent a fundamental  change in the  information set
                         forth in this Registration Statement;

                  (iii)  To include any material information with respect to the
                         plan of distribution  not previously  disclosed in this
                         Registration  Statement or any material  change to such
                         information in this Registration Statement;

                  provided,   however,   that  the  undertakings  set  forth  in
                  paragraphs  (a)(i)  and  (a)(ii)  above  do not  apply  if the
                  information  required  to  be  included  in  a  post-effective
                  amendment by those paragraphs is contained in periodic reports
                  filed  with or  furnished  to the  Commission  by the  Company
                  pursuant to Section 13 or Section  15(d) of the  Exchange  Act
                  that  are  incorporated  by  reference  in  this  Registration
                  Statement.

            (b)   That, for the purpose of determining  any liability  under the
                  Securities   Act,  each   post-effective   amendment  to  this
                  Registration   Statement   shall  be   deemed   to  be  a  new
                  registration  statement  relating  to the  securities  offered
                  therein,  and the  offering  of such  securities  at that time
                  shall be deemed to be the initial bona fide offering thereof.

            (c)   To  remove  from  registration  by means  of a  post-effective
                  amendment any of the securities  being  registered that remain
                  unsold at the termination of the offering.

(2)         The Company hereby  undertakes that, for purposes of determining any
liability under the Securities  Act, each filing of the Company's  annual report
pursuant  to  Section  13(a)  or  Section  15(d)  of the  Exchange  Act  that is
incorporated by reference in this Registration Statement shall be deemed to be a
new registration  statement relating to the securities offered therein,  and the
offering of such  securities at that time shall be deemed to be the initial bona
fide offering thereof.


                                      -3-
<PAGE>


(3)         Insofar  as  indemnification   for  liabilities  arising  under  the
Securities Act may be permitted to directors,  officers and controlling  persons
of the Company pursuant to the foregoing provisions,  or otherwise,  the Company
has been advised that in the opinion of the Commission such  indemnification  is
against  public  policy as expressed in the  Securities  Act and is,  therefore,
unenforceable.  In the  event  that a claim  for  indemnification  against  such
liabilities  (other than the payment by the Company of expenses incurred or paid
by a director,  officer or  controlling  person of the Company in the successful
defense of any action, suit or proceeding) is asserted by such director, officer
or controlling  person in connection with the securities being  registered,  the
Company  will,  unless in the opinion of its counsel the matter has been settled
by  controlling  precedent,  submit to a court of appropriate  jurisdiction  the
question  whether  such  indemnification  by  it is  against  public  policy  as
expressed in the Securities  Act and will be governed by the final  adjudication
of such issue.


                                      -4-
<PAGE>


                                   SIGNATURES


      Pursuant to the requirements of the Securities Act of 1933, the Registrant
certifies  that it has  reasonable  grounds to believe  that it meets all of the
requirements  for  filing  on Form S-8 and has  duly  caused  this  Registration
Statement  to be  signed  on its  behalf  by  the  undersigned,  thereunto  duly
authorized,  in the City of Garden Grove, State of California,  on this 14th day
of May, 2003.

                               HYCOR BIOMEDICAL INC.



                               By:/s/ J. David Tholen
                                  ----------------------------
                                  J. DAVID THOLEN, PRESIDENT AND
                                  CHIEF EXECUTIVE OFFICER


                                POWER OF ATTORNEY

      KNOW ALL MEN BY THESE PRESENTS,  that each person whose signature  appears
below  constitutes  and appoints J. David Tholen and Reginald P. Jones,  jointly
and severally, his or her attorneys-in-fact, each with power of substitution for
him or  her  in  any  and  all  capacities,  to  sign  any  amendments  to  this
Registration  Statement,  and to file the same, with the exhibits  thereto,  and
other  documents  in  connection  therewith,  with the  Securities  and Exchange
Commission   hereby   ratifying   and   confirming   all   that   each  of  said
attorneys-in-fact,  or his substitute or substitutes, may do or cause to be done
by virtue hereof.

      Pursuant  to  the  requirements  of  the  Securities  Act  of  1933,  this
Registration  Statement  has  been  signed  by  the  following  persons  in  the
capacities and on the date indicated:

                  Signature                              Date
                  ---------                              ----

      /s/ J. David Tholen                            May 14, 2003
      --------------------------
      J. DAVID THOLEN, PRESIDENT, CHIEF
      EXECUTIVE OFFICER AND DIRECTOR
      (PRINCIPAL EXECUTIVE OFFICER)

      /s/  Reginald P. Jones                         May 14, 2003
      --------------------------
      REGINALD P. JONES, SENIOR VICE PRESIDENT,
      CHIEF FINANCIAL OFFICER AND DIRECTOR
      (PRINCIPAL FINANCIAL OFFICER)

      /s/ Armando Correa                             May 14, 2003
      --------------------------
      ARMANDO CORREA,
      DIRECTOR, FINANCE
      (PRINCIPAL ACCOUNTING OFFICER)

      /s/  Samuel D. Anderson                        May 14, 2003
      --------------------------
      SAMUEL D. ANDERSON, CHAIRMAN

                                                     May __, 2003
      --------------------------
      DAVID S. GORDON, DIRECTOR

      /s/ James R. Phelps                            May 14, 2003
      --------------------------
      JAMES R. PHELPS, DIRECTOR

      /s/ Richard E. Schmidt                         May 14, 2003
      --------------------------
      RICHARD E. SCHMIDT, DIRECTOR


                                      -5-
<PAGE>


                                INDEX TO EXHIBITS


Exhibit
Number      Description
------      -----------

   4        Hycor Biomedical Inc. 2001 Stock Option Plan  (incorporated by
            reference  as Exhibit A to the  Company's  Schedule  14A filed
            with the Commission on May 2, 2001).

   5        Opinion  of Paul,  Hastings,  Janofsky  & Walker LLP as to the
            legality of the securities being registered.

 23.1       Consent of Deloitte & Touche LLP.

 23.2       Consent of Paul, Hastings,  Janofsky & Walker LLP (included in
            the opinion filed as Exhibit 5).

  24        Power of Attorney  authorizing J. David Tholen and Reginald P.
            Jones to sign  amendments  to this  Registration  Statement on
            behalf of officers and directors of the Registrant  (contained
            on Signature Page of Registration Statement).


                                      -6-
[{"type": "S-8", "sequence": "1", "filename": "hys8.txt", "secsgml_size_bytes": 16169}]
{"company-data": {"conformed-name": "HYCOR BIOMEDICAL INC /DE/", "cik": "0000719447", "assigned-sic": "2835", "irs-number": "581437178", "state-of-incorporation": "DE", "fiscal-year-end": "1231"}, "filing-values": {"form-type": "S-8", "act": "33", "file-number": "333-105250", "film-number": "03702422"}, "business-address": {"street1": "7272 CHAPMAN AVE", "city": "GARDEN GROVE", "state": "CA", "zip": "92841", "phone": "7149333000"}, "mail-address": {"street2": "7272 CHAPMAN AVENUE", "city": "GARDEN GROVE", "state": "CA", "zip": "92841"}, "former-company": {"former-conformed-name": "HYBRIDOMA SCIENCES INC", "date-changed": "19860813"}}
As filed with the Securities and Exchange Commission on May 14, 2003
                                                    Registration No. 333________

================================================================================

                                  UNITED STATES
                       SECURITIES AND EXCHANGE COMMISSION
                             WASHINGTON, D.C. 20549
                                  -------------

                                    FORM S-8
                             REGISTRATION STATEMENT
                        UNDER THE SECURITIES ACT OF 1933
                                  -------------

                              HYCOR BIOMEDICAL INC.
             (Exact name of registrant as specified in its charter)

               Delaware                                58-1437178
     (State or other jurisdiction of        (I.R.S. Employer Identification No.)
     incorporation or organization)

    7272 Chapman Avenue                                             92841
  Garden Grove, California                                       (Zip Code)
   (Address of Principal
     Executive Offices)

                                 --------------

                              HYCOR BIOMEDICAL INC.
                             2001 STOCK OPTION PLAN
                            (Full title of the plan)

                                 --------------

                                Reginald P. Jones
                Senior Vice President and Chief Financial Officer
                              Hycor Biomedical Inc.
                               7272 Chapman Avenue
                         Garden Grove, California 92841
                     (Name and address of agent for service)

                                 (714) 933-3000
          (Telephone number, including area code, of agent for service)

                 Please address a copy of all communications to:
                             Stephen D. Cooke, Esq.
                      Paul, Hastings, Janofsky & Walker LLP
                              695 Town Center Drive
                                Seventeenth Floor
                        Costa Mesa, California 92626-1924
                                 (714) 668-6200
                                 --------------
CALCULATION OF REGISTRATION FEE
====================================================================================================================================
                                                              Proposed maximum
  Title of each class of securities     Amount to be           offering price         Proposed maximum              Amount of
         to be registered                registered             per share(1)      aggregate offering price      registration fee
------------------------------------------------------------------------------------------------------------------------------------
Common Stock,
   par value $0.01 per share           1,000,000 shares             $2.95                   $2,948,320                   $238.52
====================================================================================================================================
(1)  361,000  shares were  calculated  pursuant  to Rule  457(h)(1)  at an
aggregate offering price of $724,600.  639,000 shares were calculated  pursuant
to Rules  457(c) and  457(h)(1),  based on the  average of the high and low sale
prices  ($3.48 per share) of the Common  Stock of the  Registrant  on the Nasdaq
Stock Market on May 13, 2003.
================================================================================
PART I

              INFORMATION REQUIRED IN THE SECTION 10(a) PROSPECTUS

ITEM 1.     Plan Information*

ITEM 2.     Registrant Information and Employee Plan Annual Information*

            *Information required by Part I to be contained in the Section 10(a)
            prospectus is omitted from the Registration  Statement in accordance
            with Rule 428(a)(1)  under the Securities Act and the Note to Part I
            of Form S-8.

                                     PART II

               INFORMATION REQUIRED IN THE REGISTRATION STATEMENT

ITEM 3.     INCORPORATION OF DOCUMENTS BY REFERENCE

            The   following   documents  are  hereby   incorporated   into  this
            Registration Statement and made a part hereof by this reference:

            (a)  The Annual  Report on Form 10-K of Hycor  Biomedical  Inc. (the
                 "Company") for the fiscal year ended  December 31, 2002,  filed
                 with the  Securities  and  Exchange  Commission  ("Commission")
                 pursuant to the  Securities  Exchange  Act of 1934,  as amended
                 (the "Exchange Act");

            (b)  All other reports  filed  pursuant to Section 13(a) or 15(d) of
                 the  Exchange  Act since the end of the fiscal year  covered by
                 the Registrant document referred to in (a) above; and

            (c)  The  description of the common stock contained in the Company's
                 registration  statement  filed under Section 12 of the Exchange
                 Act, including any amendment or report filed for the purpose of
                 updating such description.

           In addition,  all documents  filed by the Company with the Commission
pursuant to Sections  13(a),  13(c),  14 and 15(d) of the Exchange Act, prior to
the filing of a  post-effective  amendment  which  indicates that all securities
offered  have been  sold or which  deregisters  all  securities  then  remaining
unsold,  shall be deemed to be incorporated by reference into this  Registration
Statement and to be a part hereof from the date of filing of such documents with
the Commission.

ITEM 4.     DESCRIPTION OF SECURITIES

            Not applicable.

ITEM 5.     INTERESTS OF NAMED EXPERTS AND COUNSEL

            Not applicable.

ITEM 6.     INDEMNIFICATION OF DIRECTORS AND OFFICERS

           Section 145 of the  Delaware  General  Corporation  Law  authorizes a
court to award, or a corporation's  Board of Directors to grant  indemnification
to  directors  and  officers  in  terms   sufficiently   broad  to  permit  such
indemnification under certain circumstances against reasonable expenses incurred
in defending  against a claim.  Article Twelfth of the Company's  Certificate of
Incorporation,  as  amended,  provides  for  indemnification  of its  directors,
officers,  employees  and other  agents to the maximum  extent  permitted by the
Delaware  General   Corporation  law.  The  bylaws  of  the  Registrant  provide
indemnification of its officers and directors to the fullest extent authorized.

ITEM 7.     EXEMPTION FROM REGISTRATION CLAIMED

            Not applicable.
ITEM 8.     EXHIBITS

            The exhibits  filed as part of this  Registration  Statement  are as
            follows:

     4      Hycor Biomedical Inc. 2001 Stock Option Plan  (incorporated by
            reference  as Exhibit A to the  Company's  Schedule  14A filed
            with the Commission on May 2, 2001).

     5      Opinion of Paul, Hastings, Janofsky & Walker LLP as to the
            legality of the securities being registered.

   23.1     Consent of Deloitte & Touche LLP.

   23.2     Consent of Paul, Hastings,  Janofsky & Walker LLP (included in
            the opinion filed as Exhibit 5).

    24      Power of Attorney  authorizing J. David Tholen and Reginald P.
            Jones to sign  amendments  to this  Registration  Statement on
            behalf of officers and directors of the Registrant  (contained
            on Signature Page of Registration Statement)

ITEM 9.     UNDERTAKINGS

(1)         The Company hereby undertakes:

            (a)   To file,  during any period in which offers or sales are being
                  made,  a   post-effective   amendment  to  this   Registration
                  Statement:

                  (i)    To include any prospectus  required by Section 10(a)(3)
                         of the Securities Act;

                  (ii)   To  reflect  in the  prospectus  any  facts  or  events
                         arising after the effective  date of this  Registration
                         Statement (or the most recent post-effective  amendment
                         thereof)  which,  individually  or  in  the  aggregate,
                         represent a fundamental  change in the  information set
                         forth in this Registration Statement;

                  (iii)  To include any material information with respect to the
                         plan of distribution  not previously  disclosed in this
                         Registration  Statement or any material  change to such
                         information in this Registration Statement;

                  provided,   however,   that  the  undertakings  set  forth  in
                  paragraphs  (a)(i)  and  (a)(ii)  above  do not  apply  if the
                  information  required  to  be  included  in  a  post-effective
                  amendment by those paragraphs is contained in periodic reports
                  filed  with or  furnished  to the  Commission  by the  Company
                  pursuant to Section 13 or Section  15(d) of the  Exchange  Act
                  that  are  incorporated  by  reference  in  this  Registration
                  Statement.

            (b)   That, for the purpose of determining  any liability  under the
                  Securities   Act,  each   post-effective   amendment  to  this
                  Registration   Statement   shall  be   deemed   to  be  a  new
                  registration  statement  relating  to the  securities  offered
                  therein,  and the  offering  of such  securities  at that time
                  shall be deemed to be the initial bona fide offering thereof.

            (c)   To  remove  from  registration  by means  of a  post-effective
                  amendment any of the securities  being  registered that remain
                  unsold at the termination of the offering.

(2)         The Company hereby  undertakes that, for purposes of determining any
liability under the Securities  Act, each filing of the Company's  annual report
pursuant  to  Section  13(a)  or  Section  15(d)  of the  Exchange  Act  that is
incorporated by reference in this Registration Statement shall be deemed to be a
new registration  statement relating to the securities offered therein,  and the
offering of such  securities at that time shall be deemed to be the initial bona
fide offering thereof.

                                      -3-
(3)         Insofar  as  indemnification   for  liabilities  arising  under  the
Securities Act may be permitted to directors,  officers and controlling  persons
of the Company pursuant to the foregoing provisions,  or otherwise,  the Company
has been advised that in the opinion of the Commission such  indemnification  is
against  public  policy as expressed in the  Securities  Act and is,  therefore,
unenforceable.  In the  event  that a claim  for  indemnification  against  such
liabilities  (other than the payment by the Company of expenses incurred or paid
by a director,  officer or  controlling  person of the Company in the successful
defense of any action, suit or proceeding) is asserted by such director, officer
or controlling  person in connection with the securities being  registered,  the
Company  will,  unless in the opinion of its counsel the matter has been settled
by  controlling  precedent,  submit to a court of appropriate  jurisdiction  the
question  whether  such  indemnification  by  it is  against  public  policy  as
expressed in the Securities  Act and will be governed by the final  adjudication
of such issue.

                                      -4-
SIGNATURES

      Pursuant to the requirements of the Securities Act of 1933, the Registrant
certifies  that it has  reasonable  grounds to believe  that it meets all of the
requirements  for  filing  on Form S-8 and has  duly  caused  this  Registration
Statement  to be  signed  on its  behalf  by  the  undersigned,  thereunto  duly
authorized,  in the City of Garden Grove, State of California,  on this 14th day
of May, 2003.

                               HYCOR BIOMEDICAL INC.

                               By:/s/ J. David Tholen
                                  ----------------------------
                                  J. DAVID THOLEN, PRESIDENT AND
                                  CHIEF EXECUTIVE OFFICER

                                POWER OF ATTORNEY

      KNOW ALL MEN BY THESE PRESENTS,  that each person whose signature  appears
below  constitutes  and appoints J. David Tholen and Reginald P. Jones,  jointly
and severally, his or her attorneys-in-fact, each with power of substitution for
him or  her  in  any  and  all  capacities,  to  sign  any  amendments  to  this
Registration  Statement,  and to file the same, with the exhibits  thereto,  and
other  documents  in  connection  therewith,  with the  Securities  and Exchange
Commission   hereby   ratifying   and   confirming   all   that   each  of  said
attorneys-in-fact,  or his substitute or substitutes, may do or cause to be done
by virtue hereof.

      Pursuant  to  the  requirements  of  the  Securities  Act  of  1933,  this
Registration  Statement  has  been  signed  by  the  following  persons  in  the
capacities and on the date indicated:

                  Signature                              Date
                  ---------                              ----

      /s/ J. David Tholen                            May 14, 2003
      --------------------------
      J. DAVID THOLEN, PRESIDENT, CHIEF
      EXECUTIVE OFFICER AND DIRECTOR
      (PRINCIPAL EXECUTIVE OFFICER)

      /s/  Reginald P. Jones                         May 14, 2003
      --------------------------
      REGINALD P. JONES, SENIOR VICE PRESIDENT,
      CHIEF FINANCIAL OFFICER AND DIRECTOR
      (PRINCIPAL FINANCIAL OFFICER)

      /s/ Armando Correa                             May 14, 2003
      --------------------------
      ARMANDO CORREA,
      DIRECTOR, FINANCE
      (PRINCIPAL ACCOUNTING OFFICER)

      /s/  Samuel D. Anderson                        May 14, 2003
      --------------------------
      SAMUEL D. ANDERSON, CHAIRMAN

                                                     May __, 2003
      --------------------------
      DAVID S. GORDON, DIRECTOR

      /s/ James R. Phelps                            May 14, 2003
      --------------------------
      JAMES R. PHELPS, DIRECTOR

      /s/ Richard E. Schmidt                         May 14, 2003
      --------------------------
      RICHARD E. SCHMIDT, DIRECTOR

                                      -5-
INDEX TO EXHIBITS

Exhibit
Number      Description
------      -----------

   4        Hycor Biomedical Inc. 2001 Stock Option Plan  (incorporated by
            reference  as Exhibit A to the  Company's  Schedule  14A filed
            with the Commission on May 2, 2001).

   5        Opinion  of Paul,  Hastings,  Janofsky  & Walker LLP as to the
            legality of the securities being registered.

 23.1       Consent of Deloitte & Touche LLP.

 23.2       Consent of Paul, Hastings,  Janofsky & Walker LLP (included in
            the opinion filed as Exhibit 5).

  24        Power of Attorney  authorizing J. David Tholen and Reginald P.
            Jones to sign  amendments  to this  Registration  Statement on
            behalf of officers and directors of the Registrant  (contained
            on Signature Page of Registration Statement).

                                      -6-